IGM Biosciences Inc. (IGMS)
undefined
undefined%
At close: undefined
7.17
-4.65%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.

The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).

It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.

It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.

The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.

IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGM Biosciences Inc.
IGM Biosciences Inc. logo
Country United States
IPO Date Sep 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 198
CEO Mary Beth Harler M.D.

Contact Details

Address:
325 East Middlefield Road
Mountain View, California
United States
Website https://igmbio.com

Stock Details

Ticker Symbol IGMS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001496323
CUSIP Number 449585108
ISIN Number US4495851085
Employer ID 77-0349194
SIC Code 2834

Key Executives

Name Position
Mary Beth Harler M.D. Chief Executive Officer & Director
Misbah Tahir CPA Chief Financial Officer
Dr. Angus M. Sinclair Ph.D. Executive Vice President of Research
Dr. Elizabeth Haanes J.D., Ph.D. Senior Vice President of Intellectual Property
Dr. Lisa L. Decker Ph.D. Chief Business Officer
Dr. Marvin S. Peterson Ph.D. Executive Vice President of Process Development & Manufacturing
Paul C. Graffagnino J.D. Senior Vice President of Legal Affairs
Steven Weber Senior Vice President, Corporate Controller & Principal Accounting Officer
Suzette Tauber Chief Human Resources Officer
TS Harigopal Senior Vice President of Group Operations

Latest SEC Filings

Date Type Title
Nov 20, 2024 4 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 4 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 08, 2024 8-K Current Report
Nov 08, 2024 8-K/A [Amend] Current Report
Nov 08, 2024 10-Q Quarterly Report
Oct 04, 2024 4 Filing
Oct 03, 2024 8-K Current Report
Oct 02, 2024 4 Filing